Cochrane review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis in travellers

Evidence-Based Medicine

Volumn 15, Issue 1, 2010, Pages 25-26

  Schlagenhauf, Patricia ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE PLUS PROGUANIL; DOXYCYCLINE; MEFLOQUINE; PRIMAQUINE;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALARIA; MEDICAL RESEARCH; NOTE; SEX DIFFERENCE; TRAVEL; UNSPECIFIED SIDE EFFECT;

EID: 77249123339     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1021     Document Type: Note

References (5)

1. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003;327:1078.
2. Schlagenhauf P, Abo El Ela H, Neiderberger W, et al. Drug safety database analysis of the serious adverse events (SAE) "depression" or "suicide" reported in association with the use of mefl oquine. Proceedings of the 7th Conference of the International Society of Travel Medicine, 27-31 May 2001, Innsbruck, Austria.
3. Wells TS, Smith TC, Smith B, et al. Mefl oquine use and hospitalizations among US service members, 2002-2004. Am J Trop Med Hyg 2006;74:744-9.
4. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004;27:203-13.
5. Schlagenhauf P, Chen L, Wilson M. Gender and travel associated illness. Clin Infect Dis 2010; in press.